Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This gene encodes a long non-coding RNA (lncRNA) that is transcribed in the antisense orientation to the USP51 gene. Antisense lncRNAs frequently play regulatory roles in controlling expression of their associated sense genes, often through mechanisms involving chromatin modulation, transcription interference, or direct RNA interactions. While this specific transcript (ENSG00000288739) does not have a well-characterized function, antisense transcription in general can locally modify chromatin architecture, regulate transcription rates, and potentially affect gene expression of USP51. No clinical or drug interaction data are available for this target, and it is not currently classified as a therapeutic target.
Chromatin modification (by analogy with the broader class of antisense RNAs; lncRNAs can recruit chromatin modifiers or impact chromatin status near their sense gene targets) Regulation of sense (USP51) gene expression (general role inferred for antisense lncRNAs)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to USP51.